Precigen Inc
NASDAQ:PGEN

Watchlist Manager
Precigen Inc Logo
Precigen Inc
NASDAQ:PGEN
Watchlist
Price: 3.51 USD Market Closed
Market Cap: 1.2B USD

Precigen Inc
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Precigen Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Precigen Inc
NASDAQ:PGEN
Selling, General & Administrative
-$63.5m
CAGR 3-Years
-10%
CAGR 5-Years
6%
CAGR 10-Years
2%
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.8B
CAGR 3-Years
-3%
CAGR 5-Years
-5%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7B
CAGR 3-Years
-10%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$3.2B
CAGR 3-Years
-17%
CAGR 5-Years
-15%
CAGR 10-Years
-16%
No Stocks Found

Precigen Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 456 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The firm also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. The company also has a robust pipeline of preclinical programs.

PGEN Intrinsic Value
2.18 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Precigen Inc's Selling, General & Administrative?
Selling, General & Administrative
-63.5m USD

Based on the financial report for Sep 30, 2025, Precigen Inc's Selling, General & Administrative amounts to -63.5m USD.

What is Precigen Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
2%

Over the last year, the Selling, General & Administrative growth was -57%. The average annual Selling, General & Administrative growth rates for Precigen Inc have been -10% over the past three years , 6% over the past five years , and 2% over the past ten years .

Back to Top